Repeat Deviations and OOS: Strengthening RCA-CAPA Effectiveness and Managing Investigation Backlogs | Risk-Based Decisions on When to Investigate Deeper, Escalate, or Close

Repeat deviations, repeat OOS results, and repeat market complaints all raise the same uncomfortable question in different forms.

• Is this genuinely the same problem returning, a similar event with a different cause, or the first visible sign of something systemic?
• Does recurrence mean the previous investigation was inadequate?
• Was the root cause wrong?
• Did the CAPA fail, or was it never actually capable of preventing recurrence in the first place?
• And when several individually minor events across deviations, OOS, and complaints begin pointing in the same direction, at what point does their combined significance demand a different response?

This 2-hour webinar examines these decisions alongside two connected operational realities: growing investigation and CAPA backlogs, and the recurring problem of root cause analysis (RCA) that looks complete on paper but fails to prevent the next occurrence. Every open record cannot receive unlimited investigation, yet closure simply to meet aging targets can leave important questions, and weak CAPAs unresolved. Risk, recurrence, product and process impact, previous history, strength of evidence, and effectiveness of earlier actions all influence how much investigation is justified and where limited resources should be concentrated.

The session brings these factors together around the decisions that matter in practice: when to keep digging, when to widen the investigation, when an issue needs escalation, whether CAPA is actually warranted, why RCA so often fails to hold up on repeat, and when the available evidence is sufficient to close. It also examines how apparently separate events across deviations, OOS, and complaints can change significance when viewed collectively, how to build and use Quality Risk Management (QRM) more meaningfully into CAPA decision-making rather than as a documentation formality, and how backlog pressure can be managed without allowing age or closure metrics to drive the wrong decisions.

| AREAS COVERED

• How to identify repeat and recurring deviations, OOS results, and market complaints when events are similar, but not identical
• When recurrence changes the risk and calls for deeper investigation
• Minor individually, significant collectively: recognizing when multiple events across deviations, OOS, and complaints point to a systemic problem
• How far should the investigation go? Expanding scope, reopening previous findings, and knowing when escalation is warranted
• Why RCA fails on repeat: common failure patterns and how to recognize an RCA that won't hold
• Challenging previous root-cause conclusions when the problem returns
• Is CAPA actually required? If yes, when exactly, and is it addressing the real cause or just the latest symptom?
• Strengthening CAPA effectiveness through QRM
• Using risk tools (not just risk ratings) to size the CAPA response to the actual risk
• Testing whether an action is likely to actually work before it's implemented
• CAPA backlogs and aging investigations: risk-based vs. age-based prioritization
• Avoiding over-investigation and premature closure: how much evidence is enough to make the closure decision, including for CAPA effectiveness checks themselves

| WHO SHOULD ATTEND

• Quality Assurance Departments
• Quality Control Departments
• Regulatory Affairs Departments
• Manufacturing Departments
• Operations Departments
• Validation and Engineering Departments
• Technical Operations Teams
• Site and Quality Management

Course Director: G. Sundar

G. Sundar is a quality practitioner with vast 35 years’ experience in the field of Quality Assurance, Quality Control, Bioequivalence and Pharmaceutical Regulations. His quality management experience covers the implementation of Quality tools in bulk drugs, formulation companies and CRO. He is an expert in Total Quality Systems as per GLP, GDP and as per EMEA, USFDA, MHRA and MCC, TGA, ANVISA, Japan guidelines. He has conducted more than 200 GMP/GLP audits including Q10 & Q11 implementation, 50 Formulation Contract Manufacturing Units (all types of formulations), 10 Contract Research and Analytical laboratories, 10 Clinical research CROs. He has also conducted 1000 plus trainings Asia, US, EU, Middle East and South-East Asia. Mr. Sundar Ganesan is the Director and Senior Consultant at PharmQA Compliance Services.